Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DexComDXCM +0.39%92 3-Year EBITDA Growth Rate is 36.30% as of Mar. 2026, which is 102% above its 10-year median of 17.95. GuruFocus rates DXCM with a GF Score™ of 92/100 and a GF Value™ of $104.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 691 Medical Devices & Instruments companies, DexCom ranks better than 81.77% on this metric.
During the past 12 months, DexCom's average EBITDA Per Share Growth Rate was 54.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 36.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 31.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of DexCom was 37.50% per year. The lowest was -24.90% per year. And the median was 17.95% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
DexCom 3-Year EBITDA Growth Rate Related Terms
DXCM vs GEHC, STE, ZBH: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, DexCom's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where DexCom's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 36.30% mean?
DexCom (DXCM) has a 3-Year EBITDA Growth Rate of 36.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for DexCom and its competitors. This is 102% above median its historical median of 17.95. According to the industry distribution chart, DexCom ranks #126 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 18.2%.
Is DexCom's 3-Year EBITDA Growth Rate too high?
DexCom's current 3-Year EBITDA Growth Rate of 36.30% is 102% above median its 10-year median of 17.95. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. DexCom's value of 36.30% is 348.1% above this industry median. Based on the distribution chart, DexCom ranks #126 out of 691 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, DexCom has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's 3-Year EBITDA Growth Rate compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #126 out of 691 companies for 3-Year EBITDA Growth Rate. This places DexCom in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. DexCom's value of 36.30% is 348.1% above this benchmark. While the company's 10-year median is 17.95 vs. the industry median of 8.10, DexCom has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexCom's current 3-Year EBITDA Growth Rate of 36.30% is 348.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for DexCom and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current 3-Year EBITDA Growth Rate is 36.30%, which is 102% above median its own 10-year median of 17.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Modestly Undervalued. The stock's GF Value™ is $104.89, compared to a current price of $75.14 — trading 28.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 36.30%, which is 102% above median its 10-year median of 17.95 and 348.1% above the Medical Devices & Instruments industry median of 8.10. DexCom's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For DexCom (DXCM), the current 3-Year EBITDA Growth Rate is 36.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of $75.14 is trading 28.4% below its estimated GF Value™ of $104.89.
GuruFocus considers DexCom to be Modestly Undervalued.
Key valuation signals for DXCM:
3-Year EBITDA Growth Rate: 36.30% (102% above median its 10-year median of 17.95)
GF Value™: $104.89 vs. price of $75.14 (28.4% below fair value)
Industry Position: 348.1% above the Medical Devices & Instruments median (#126 of 691)
No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
92GF Score
Get the complete analysis for DXCM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DXCM has been successfully added to your 
